Commonwealth Equity Services
PCSA icon

Commonwealth Equity Services’s Processa Pharmaceuticals PCSA Stock Holding History

Commonwealth Equity Services’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21
Closed -$115K – 3561
2021
Q1 		$115K Buy
+21
New +$97.9K ﹤0.01% 3243

Other funds holding PCSA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

Commonwealth Equity Services's PCSA Position: Q2 2021 in Review

Commonwealth Equity Services sold out of Processa Pharmaceuticals (PCSA) in Q2 2021, closing a stake of 21 shares — an estimated $115K sold.

Commonwealth Equity Services first reported a position in PCSA in Q1 2021 and held it in 1 quarter. The position peaked at $115K in Q1 2021. 16 funds tracked by Wall St. Rank hold PCSA as of Q2 2021.

  • Commonwealth Equity Services reported no remaining Processa Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Commonwealth Equity Services sold 21 Processa Pharmaceuticals shares in Q2 2021, an estimated $115K.
  • Commonwealth Equity Services first reported a position in Processa Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Commonwealth Equity Services's Processa Pharmaceuticals position peaked at $115K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2021.

Based on Commonwealth Equity Services's 13F filing for Q2 2021, filed 11 Aug 2021.